Skip to main content
Top
Published in: CEN Case Reports 2/2020

01-05-2020 | Kidney Injury | Case Report

Carboplatin-related acute interstitial nephritis in a patient with pancreatic neuroendocrine tumor

Authors: Akimasa Asai, Takayuki Katsuno, Makoto Yamaguchi, Shiho Iwagaitsu, Hironobu Nobata, Hiroshi Kinashi, Hiroshi Kitamura, Shogo Banno, Yasuhiko Ito

Published in: CEN Case Reports | Issue 2/2020

Login to get access

Abstract

Carboplatin is characterized by low nephrotoxicity, including acute tubular necrosis (ATN), compared to a conventional platinum complex due to its low accumulative property in the renal tubules. Therefore, there are extremely few reports of carboplatin-induced kidney injury and only one case has been histologically examined. Herein, we describe the case of a 53-year-old man who presented with acute kidney injury (AKI) that occurred after carboplatin administration and was diagnosed with biopsy-proven acute interstitial nephritis (AIN). To our knowledge, this is the second case report of carboplatin-related AIN. The patient was diagnosed with a pancreatic neuroendocrine tumor, and chemotherapy consisting of cisplatin and irinotecan was initiated. However, 1 week later, he was admitted to our institution with fever, fatigue and an increase in C-reactive protein (CRP) level. The chemotherapy regimen was altered to carboplatin and etoposide, but high fever occurred on the first day, and CRP re-elevation and AKI became apparent 9 days later. Renal biopsy revealed prominent inflammatory cell infiltration into the interstitium, which lead to the pathological diagnosis of AIN. On immunostaining for surface markers, CD3- and CD68-positive cells were found to be predominant, and CD20-positive cells were relatively few. Although the serum creatinine level increased to 6.81 mg/dL, it decreased to 1.43 mg/dL 15 days after steroid therapy. This case demonstrated that carboplatin-related kidney injury includes not only ATN but also AIN. Appropriate pathological diagnosis including renal biopsy and indications for steroid treatment should be carefully considered.
Literature
1.
go back to reference Arany I, Safirstein RL. Cisplatin nephrotoxicity. Semin Nephrol. 2003;23:460–4.CrossRef Arany I, Safirstein RL. Cisplatin nephrotoxicity. Semin Nephrol. 2003;23:460–4.CrossRef
2.
go back to reference Dobyan DC, Levi J, Jacobs C, Kosek J, Weiner MW. Mechanism of cis-platinum nephrotoxicity: II. Morphologic observations. J Pharmacol Exp Ther. 1980;213:551–6.PubMed Dobyan DC, Levi J, Jacobs C, Kosek J, Weiner MW. Mechanism of cis-platinum nephrotoxicity: II. Morphologic observations. J Pharmacol Exp Ther. 1980;213:551–6.PubMed
3.
go back to reference Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 2008;73:994–1007.CrossRef Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 2008;73:994–1007.CrossRef
4.
go back to reference Yonezawa A, Masuda S, Yokoo S, Katsura T, Inui K. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006;319:879–86.CrossRef Yonezawa A, Masuda S, Yokoo S, Katsura T, Inui K. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006;319:879–86.CrossRef
5.
go back to reference Haas M, Spargo BH, Wit EJ, Meehan SM. Etiologies and outcome of acute renal insufficiency in older adults a renal biopsy study of 259 cases. Am J Kidney Dis. 2000;35:433–47.CrossRef Haas M, Spargo BH, Wit EJ, Meehan SM. Etiologies and outcome of acute renal insufficiency in older adults a renal biopsy study of 259 cases. Am J Kidney Dis. 2000;35:433–47.CrossRef
6.
go back to reference Praga M, González E. Acute interstitial nephritis. Kidney Int. 2010;77:956–61.CrossRef Praga M, González E. Acute interstitial nephritis. Kidney Int. 2010;77:956–61.CrossRef
7.
go back to reference Baker RJ, Pusey CD. The changing profile of acute tubulointerstitial nephritis. Nephrol Dial Transplant. 2004;19:8–11.CrossRef Baker RJ, Pusey CD. The changing profile of acute tubulointerstitial nephritis. Nephrol Dial Transplant. 2004;19:8–11.CrossRef
8.
go back to reference Perazella MA, Markowitz GS. Drug-induced acute interstitial nephritis. Nat Rev Nephrol. 2010;6:461–70.CrossRef Perazella MA, Markowitz GS. Drug-induced acute interstitial nephritis. Nat Rev Nephrol. 2010;6:461–70.CrossRef
9.
go back to reference Rossert J. Drug-induced acute interstitial nephritis. Kidney Int. 2001;60:804–17.CrossRef Rossert J. Drug-induced acute interstitial nephritis. Kidney Int. 2001;60:804–17.CrossRef
10.
go back to reference González E, Gutiérrez E, Galeano C, Chevia C, de Sequera P, Bernis C, Parra EG, Delgado R, Sanz M, Ortiz M, Goicoechea M, Quereda C, Olea T, Bouarich H, Hernández Y, Segovia B, Praga M. Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis. Kidney Int. 2008;73:940–6.CrossRef González E, Gutiérrez E, Galeano C, Chevia C, de Sequera P, Bernis C, Parra EG, Delgado R, Sanz M, Ortiz M, Goicoechea M, Quereda C, Olea T, Bouarich H, Hernández Y, Segovia B, Praga M. Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis. Kidney Int. 2008;73:940–6.CrossRef
11.
go back to reference Clarkson MR, Giblin L, O'Connell FP, O'Kelly P, Walshe JJ, Conlon P, O'Meara Y, Dormon A, Campbell E, Donohoe J. Acute interstitial nephritis: clinical features and response to corticosteroid therapy. Nephrol Dial Transplant. 2004;19:2778–833.CrossRef Clarkson MR, Giblin L, O'Connell FP, O'Kelly P, Walshe JJ, Conlon P, O'Meara Y, Dormon A, Campbell E, Donohoe J. Acute interstitial nephritis: clinical features and response to corticosteroid therapy. Nephrol Dial Transplant. 2004;19:2778–833.CrossRef
12.
go back to reference McDonald BR, Kirmani S, Vasquez M, Mehta RL. Acute renal failure associated with the use of intraperitoneal carboplatin: a report of two cases and review of the literature. Am J Med. 1991;90:386–91.CrossRef McDonald BR, Kirmani S, Vasquez M, Mehta RL. Acute renal failure associated with the use of intraperitoneal carboplatin: a report of two cases and review of the literature. Am J Med. 1991;90:386–91.CrossRef
13.
go back to reference Berney-Meyer L, Hung N, Slatter T, Schollum JB, Kitching AR, Walker RJ. Omeprazole-induced acute interstitial nephritis: a possible Th1-Th17-mediated injury? Nephrology (Carlton). 2014;19:359–65.CrossRef Berney-Meyer L, Hung N, Slatter T, Schollum JB, Kitching AR, Walker RJ. Omeprazole-induced acute interstitial nephritis: a possible Th1-Th17-mediated injury? Nephrology (Carlton). 2014;19:359–65.CrossRef
14.
go back to reference Moledina DG, Perazella MA. Drug-induced acute interstitial nephritis. Clin J Am Soc Nephrol. 2017;12:2046–9.CrossRef Moledina DG, Perazella MA. Drug-induced acute interstitial nephritis. Clin J Am Soc Nephrol. 2017;12:2046–9.CrossRef
Metadata
Title
Carboplatin-related acute interstitial nephritis in a patient with pancreatic neuroendocrine tumor
Authors
Akimasa Asai
Takayuki Katsuno
Makoto Yamaguchi
Shiho Iwagaitsu
Hironobu Nobata
Hiroshi Kinashi
Hiroshi Kitamura
Shogo Banno
Yasuhiko Ito
Publication date
01-05-2020
Publisher
Springer Singapore
Published in
CEN Case Reports / Issue 2/2020
Electronic ISSN: 2192-4449
DOI
https://doi.org/10.1007/s13730-019-00437-w

Other articles of this Issue 2/2020

CEN Case Reports 2/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.